Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · IEX Real-Time Price · USD
23.31
+0.48 (2.13%)
Jul 22, 2024, 11:57 AM EDT - Market open
Rocket Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
268
Market Cap
2.11B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.37B |
Premier | 1.34B |
LifeStance Health Group | 1.10B |
Addus HomeCare | 1.09B |
10x Genomics | 625.45M |
Catalyst Pharmaceuticals | 411.35M |
Beam Therapeutics | 360.91M |
STAAR Surgical Company | 326.24M |
RCKT News
- 23 days ago - FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment - Investopedia
- 24 days ago - Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) - Business Wire
- 7 weeks ago - Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy - Business Wire
- 2 months ago - Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) - Business Wire
- 2 months ago - Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress - Business Wire
- 3 months ago - Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia - Business Wire
- 4 months ago - Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team - Business Wire
- 5 months ago - Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress - Business Wire